4/18
07:01 am
rvph
AbbVie buyout Cerevel posts late-stage win for Parkinson's disease drug [Seeking Alpha]
Medium
Report
AbbVie buyout Cerevel posts late-stage win for Parkinson's disease drug [Seeking Alpha]
4/16
10:13 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $17.00 price target on the stock.
Low
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $17.00 price target on the stock.
4/15
08:39 am
rvph
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia [Yahoo! Finance]
Medium
Report
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia [Yahoo! Finance]
4/15
08:30 am
rvph
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Medium
Report
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
4/15
08:07 am
rvph
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
4/15
08:05 am
rvph
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
Medium
Report
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
3/28
08:00 am
rvph
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Low
Report
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
3/26
08:00 am
rvph
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
High
Report
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
3/25
08:07 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/11
08:00 am
rvph
Reviva to Present at the UBS Virtual CNS Day
Medium
Report
Reviva to Present at the UBS Virtual CNS Day
3/7
08:00 am
rvph
Reviva to Present at the 36th Annual ROTH Conference
Low
Report
Reviva to Present at the 36th Annual ROTH Conference
2/20
08:12 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/20
08:12 am
rvph
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference [Yahoo! Finance]
Low
Report
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference [Yahoo! Finance]
2/20
08:00 am
rvph
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Low
Report
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
2/6
08:13 am
rvph
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia [Yahoo! Finance]
Low
Report
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia [Yahoo! Finance]
2/6
08:00 am
rvph
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Low
Report
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
1/25
08:06 am
rvph
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference [Yahoo! Finance]
Neutral
Report
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference [Yahoo! Finance]
1/25
08:00 am
rvph
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
Neutral
Report
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference